Monash extends collaboration with Janssen on psoriasis prevention
Monash University announced an extension of its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, where researchers will investigate triggers of the immune-mediated disease, psoriasis, and focus on the discovery of potential new treatment approaches to prevent psoriasis.
Professor Jamie Rossjohn, from the Biomedicine Discovery Institute, Faculty of Medicine, will lead the research team at Monash University on the three-year research program.
“We’re delighted to be working alongside Janssen once again in a joint effort to broaden our knowledge around this condition and develop novel treatments for psoriasis,” Professor Rossjohn said.